title: Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
abstract: We evaluated bortezomib induced peripheral neuropathy (BIPN) characteristics in an attempt to better clarify the type, grade, duration and reversibility of neuropathy as well as investigate possible peripheral neuropathy (PN) risk factors and detect the best way to manage it. We calculated the grading of neuropathy using the Total Neuropathy Score reduced version (TNSr) in a series of 51 patients with relapsed/refractory multiple myeloma treated with bortezomib. Seventy percent developed clinical PN. BIPN, although manageable, is frequently underestimated in patients treated with bortezomib intravenously. Continuous follow-up and management of PN are needed to avoid quality of life impairment.
authors.affiliation: Hematology Section, First Department of Propedeutic Internal Medicine, Laikon University Hospital , Athens , Greece.
authors.forename: Chrysothea K
authors.initials: CK
authors.lastname: Zaroulis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Chairopoulos
authors.forename: Sotirios P
authors.initials: SP
authors.lastname: Sachanas
authors.forename: Dimitris
authors.initials: D
authors.lastname: Maltezas
authors.forename: Tatiana
authors.initials: T
authors.lastname: Tzenou
authors.forename: Ilias
authors.initials: I
authors.lastname: Pessach
authors.forename: Efstathios
authors.initials: E
authors.lastname: Koulieris
authors.forename: Eleni
authors.initials: E
authors.lastname: Koutra
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kilindireas
authors.forename: Gerasimos A
authors.initials: GA
authors.lastname: Pangalis
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Kyrtsonis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009460:Neurologic Examination; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis* / Q000209:etiology*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib
keywords: Drug induced peripheral neuropathy; bortezomib; multiple myeloma